DOCSLIB.ORG

Yasakli Maddeler

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Yasakli Maddeler YASAKLI MADDELER Ülkemizde yarış atlarında kullanılan/kullanılma ihtimali olan ilaçların/maddelerin belirlenmesinde; ilacın farmakolojisi (öncelikle etkisi, etki grubu), farmasötik şekli, kullanılma yolu, kullanılma alanı, yarış sonucunu etkileme durumu, ulusal mevzuata göre veteriner hekimlikte ve/veya yarış atlarında kullanmak için ruhsatlı/izinli olup-olmama durumu, etiket-dışı kullanılma gibi hususlar dikkate alınmıştır. Eşik değeri (Threshold level) olan maddelerin (vücutta şekillenirler, çevre ve yem kaynaklı olabilirler) miktarı, belirlenen miktarı aştığında yasaklı-madde kullanılması/doping ihlali olarak değerlendirilir. Tedavide kullanılan/tarama limiti (Screening level) olan maddelerle ilgili değerlendirmede; bu maddelerle ilgili olarak yapılan doping analizlerinde ölçülen miktar, idrarda/plazmada belirlenen tarama değerini aştığında yasaklı madde kullanılması/doping-ihlali olarakdeğerlendirilir. Ana madde yanında, izomeri, metaboliti, metabolit izomeri, tuzları, esterleri, eterleri, diğer türevleri, ön-ilaç da yasaklı-madde listesinde yer alır; doping analizinde ortaya konulmaları doping ihlali olarak değerlendirilir. Maddeler ve yasaklı uygulamalar 6 başlık altında toplanmıştır. Bu liste ilgili uluslararası kuruluşların mevzuat ve düzenlemeleri ile ilgili maddelerin Farmakolojik özellikleri ve etkileri dikkate alınarak hazırlanmıştır. 1. YasaklıMaddeler Yasaklı maddeler; yarış atlarında tıbbi olarak kullanım yeri olmayan, atın yarış performansını açık şekilde etkileyen maddelerdir. İllegal kullanılan maddeler (Türkiye’de veteriner hekimlikte ruhsatlı/izinli olmayan ilaçlar/maddeler) de bu kapsamda değerlendirilir. Yasaklı maddeler, atlarda tıbbi kullanımı olabilen fakat hayvanın performansını değiştirebilen, böylece yarışın sonucunu etkileyebilen, kötüye kullanılma/istismar edilme potansiyeli olan maddeleri de kapsamaktadır. Bu liste bilgi amaçlıdır. Bu listede belirtilen İlaç etken maddelerinin yanı sıra; İFHA ‘nın (Uluslararası At yarışları Federasyonu ) koymuş olduğu kurallar gereği, farmakolojik olarak benzer etkiyi gösteren maddeler de yasaklı madde kapsamında değerlendirilir. No İlaç/Madde Adı Etkisi 1 (+)-Norpseüdoefedrin (Kathin, Catha edulis) Uyarıcı (Sempatomimetik) 2 8-Pradol (Zingiber officinale) Bitkisel yangı/tromboz önleyici 3 -Butirolakton (GBL) Sedativ Saptırıcı (Halusinojen, Psikoaktiv, Büyüme 4 -Hidroksibutirik asit (GHB) hızlandırıcı) 5 17α-Etiniltestosteron Progesteron benzeri etki 6 19-Norandrostenedion (Estr-4-ene-3β,17β-diol) Anabolik Androjenik Steroid (AAS) 7 19-Norandrosteron AAS (Testosteron metaboliti/izomeri) 8 19-Noretiokolanolon AAS (Testosteron metaboliti/izomeri) 9 1-Androstenediol (5α-androst-1-ene-3β,17β-diol) AAS 10 1-Androstenedion (5α-androst-1-ene-3β,17β-dion) AAS 11 1-Testosteron (17β-hidroksi-5α-androst-1-en-3-on) AAS 12 2,5-Dimetoksi-4-etilamfetamin (DOET) Saptırıcı (Halusinojen, Psikoaktiv) 13 2,5-Dimetoksi-4-metilamfetamin (DOM) Saptırıcı (Halusinojen, Psikoaktiv) 2-Metilserotonin (2-metil-5HT, 2-Metil-5- Antidepresan 14 hidroksitriptamin) 15 3,4-Metilendioksiamfetamin (MDA, Tenamfetamin) Saptırıcı (Halusinojen, Psikoaktiv) 16 3,4-Metilendioksietilamfetamin (MDEA) Saptırıcı (Halusinojen, Psikoaktiv) 17 3,4-Metilendioksimetamfetamin (MDMA-Ecstasy) Saptırıcı (Halusinojen, Psikoaktiv) 18 3-Oktopamin (Norfenefrin) Uyarıcı (Sempatomimetik) 19 4-Aminopridin (Fampridin) Uyarıcı 20 4-Androsten-3,6,17-trion (6-Okso) Aromataz engelleyici (Hormon modülatörü) 21 4-Androstenediol (Androst-4-ene-3β,17β-diol) AAS (Testosteron metabloliti/izomeri) 22 4-Androstenedion (Androst-4-ene-3β,17β-dion) AAS (Testosteron metabloliti/izomeri) 4-Hidroksitestosteron (4,17-dihidroksiandrost-4-en- AAS 23 3-on) 24 4-Kloroamfetamin (p-Kloroamfetamin, PCA) Uyarıcı (Amfetamin-benzeri) 25 4-Klorodehidrometiltestosteron (Turinabol) AAS 4-Metilmetkathinon (Mefedron, 4-MMC, Kathinon 26 Uyarıcı (Amfetramin-benzer) analoğu) 4-MMC (4-Metilmetkathinon, Mefedron, Kathinon Uyarıcı (Amfetamin-benzeri) 27 analoğu) 5-Aminoimidazol-4-karboksamid-1β-D- 5’-AMPK etkinleştirici 28 ribofuranosid (AICAR) 29 5-Androstenediol (Androst-5-en-3,17-dion) AAS (Testosteron metabloliti/izomeri) 30 5-Androstenedion (Androst-5-ene-3,17-dion) AAS (Testosteron metabloliti/izomeri) 31 5-MeO-DMT (5-Metoksi-N,N-dimetiltriptamin) Saptırıcı (Halusinojen, Psikoaktiv) 5-Metil-3,4-metilendioksimetamfetamin (5-metil- 32 Asptırıcı (Halusinojen, Psikoaktiv) DMA) 33 5-Metoksi-3,4-metilendioksiamfetamin (MMDA) Saptırıcı (Halusinojen, Psikoaktiv) 34 5-Metoksi-N,N-dimetiltriptamin (5-MeO-DMT) Saptırıcı (Halusinojen, Psikoaktiv) 35 5-Metoksitriptamin (5-MT, Meksamin) Saptırıcı (Halusinojen, Psikoaktiv) 36 5-MT (5-Metoksitriptamin, Meksamin) Saptırıcı (Halusinojen, Psikoaktiv) 37 5α-Androstan-3α,17α-diol AAS (Testosteron metabloliti/izomeri) 38 5α-Androstan-3α,17β-diol AAS (Testosteron metabloliti/izomeri) 39 5α-Androstan-3β,17α-diol AAS (Testosteron metabloliti/izomeri) 40 5α-Androstan-3β,17β-diol AAS (Testosteron metabloliti/izomeri) 41 5β-Androstan-3α,17β-diol AAS (Testosteron metabloliti/izomeri) 42 5,6-Metilendioksi-2-aminoindan (MDAI) Saptırıcı (Halusinojen, Psikoaktiv) 43 6-Hidroksidopamin (6-OHDA, Oksidopamin) Adrenerjik/Dopaminerjik sinir ucu tahrip edici 44 6-Okso (4-Androsten-3,6,17-trion) Aromataz engelleyici (Hormon modülatörü) 45 7-keto-DHEA AAS (Testosteron metabloliti/izomeri) 46 7α-Hidroksi-DHEA AAS (Testosteron metabloliti/izomeri) 47 7β-Hidroksi-DHEA AAS (Testosteron metabloliti/izomeri) 48 α-Etiltriptamin (αET) Saptırıcı (Halusinojen, Psikoaktiv) 49 α-Metildopa (Metildopa) Sempatomimetik/Antihipertansiv) 50 α-Metilparatirozin (AMPT) Katekolamin sentezi engelleyici 51 α-Metiltriptamin (αMT) Saptırıcı (Halusinojen, Psikoaktiv) 52 Acemetasin Ağrı kesici-ateş düşürücü-yangı önleyici 53 Adifenin Parasempatolitik 54 Adrafinil (Modafinil ön-maddesi) Uyarıcı (Amfetamin-benzeri) 55 Adrenalin (Epinefrin) Uyarıcı (Sempatomimetik) 56 Adrenokortikotropik hormon (Kortikotropin) Kortikosteroidlerin salgılanması 57 Adrenokrom Kanama kesici (Antifibrinolitik) 58 Adrenorfin (Oktapeptid) Opioid reseptör agonisti 59 Agomelatin Antidepresan AICAR (5-Aminoimidazol-4-karboksamid-1β-D- 60 5’-AMPK etkinleştirici ribofuranosid) 61 Akrivastin Antihistaminik 62 Albuterol (Salbutamol) Sempatomimetik 63 Aldosteron Mineralokortikoid 64 Albiglutid Kan şekerini düşürücü 65 Aleksamorelin BH salgılatıcı peptid 66 Alendronik asit Kemik metabolizmasına etkili 67 Alfadolon Genel anestezik (Altesin bileşeni) 68 Alfa-kloraloz Genel anestezik 69 Alfaksalon (Alfaksolon) Genel anestezik (Altesin bileşeni) 70 Alfa-prodin Opioid (-R agonisti) 71 Alfaprostol PGF2α analoğu 72 Alfentanil Opioid (-R agonisti) 73 Alfuzosin Sempatolitik 74 Aljinik asit sülfat Heparinoid 75 Alkuronium Çizgili kas gevşetici 76 Allilestrenol (Gestenon) Progesteron benzeri etki 77 Allilprodin Opioid 78 Allobarbital Sedativ-Hipnotik 79 Alloksan Kan şekerini düşürücü 80 Allopurinol Ksantin oksidaz engelleyici 81 Almotriptan Migren 82 Alniditan Migren 83 Alogliptin Kan şekerini düşürücü 84 Alpidem Psikotrop (Trankilizan) 85 Alprazolam Psikotrop (Trankilizan) 86 Alprenolol Sempatolitik 87 Alprostadil Solunum yollarını genişletici (PGE analoğu) 88 Alteplas Plazminojen etkinleştirici 89 Altesin Genel anestezik 90 Altrenogest (Allil-trenbolon) Progesteron benzeri etki 91 Altropan Antidepresan 92 Aluminyum hidroksit Maskeleyici/Tampon (Alkalileştirici) 93 Alverin Düz kas gevşetici/Spazm çözücü 94 Alvimopan Opioid antagonist/Ameliyat sonrası ileus 95 Amantadin Parkinson 96 Ambenonium Parasempatomimetik 97 Ambroksol Balgam söktürücü/Balgam eritici 98 Ambucetamid Düz kas gevşetici/Spazm çözücü 99 Amedalin Antidepresan 100 Ametokain (Tetrakain) Lokal anestezik 101 Amfenon Steroid antagonisti 102 Amfepramon (Dietilpropion, Etkathinon Uyarıcı/iştah kesici (Amfetamin-benzeri) ön- maddesi) 103 Amfetamin Uyarıcı (Amfetamin-benzeri) 104 Amfetaminil (N-Siyanobenzilamfetamin, Uyarıcı (Amfetamin-benzeri) vücutta amfetamine çevrilir) 105 Amidopirin (Aminopirin, Aminofenazon) Ağrı kesici-ateş düşürücü-yangı önleyici 106 Amifenazol Uyarıcı (Analeptik) 107 Amilnitrit Antihipertansiv/Angina 108 Amilokain Lokal anestezik 109 Amilorid İdrar söktürücü 110 Amineptin Antidepresan 111 Aminofenazon (Aminopirin, Amidopirin) Ağrı kesici-ateş düşürücü-yangı önleyici 112 Aminofilin Uyarıcı (Analeptik, Kalp analeptiği) 113 Aminoglutetimid Aromataz engelleyici/Steroid antagonisti 114 Aminokaproik asit Kanama kesici (Antifibrinilotik) 115 Aminometilbenzoik asit Kanama kesici (Antifibrinilotik) 116 Aminopirin (Amidopirin, Aminofenazon) Ağrı kesici-ateş düşürücü-yangı önleyici 117 Aminopromazin Psikotrop (Nöroleptik/Düz kas gevşetici) 118 Aminopterin Bağışıklık baskılayıcı (Folat antagonisti) 119 Aminoreks (aynı zamanda levamizol metaboliti) Uyarıcı/İştah kesici (Amfetamin-benzeri) 120 Amiodaron Antiaritmik 121 Amisometradin İdrar söktürücü 122 Amisulprid Psikotrop (Nöroleptik) 123 Amitriptilin Antidepresan 124 Amlodipin Antihipertansiv/Angina 125 Amobarbital Sedativ-Hipnotik 126 Amoksapin (Loksapin etkin metaboliti) Antidepresan 127 Amonyum klorür Maskeleyici/Tampon (Asitleştirici) 128 Amosulolol Sempatolitik 129 Amperozid Yatıştırıcı/Sakinleştirici 130 Ampiroksikam Ağrı kesici-ateş düşürücü-yangı önleyici 131 Ampiron Ağrı kesici-ateş düşürücü-yangı önleyici 132 Amrinon Kardiyotonik/Damar genişletici 133 Amsinonid Glukokortikoid (Yangı önleyici) 134 Anastrozol Aromataz engelleyici (Hormon modülatörü) 135 Andarin Anabolik 136 Androst-4-ene-3α,17α-diol AAS (Testosteron metabloliti/izomeri) 137 Androst-4-ene-3α,17β-diol AAS (Testosteron metabloliti/izomeri)
Load more

Recommended publications
  • ANNNNNNNNNNNNNNNNNNNN 100A 006 Left Eye Input Right Eye Input
    US 20190175049A1 ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2019 /0175049 A1 Welling ( 43 ) Pub . Date : Jun . 13 , 2019 ( 54 ) TECHNIQUES FOR ANALYZING (52 ) U . S . CI. NON -VERBAL MARKERS OF CONDITIONS CPC . .. A61B 5 /04842 (2013 . 01 ) ; A61B 5 / 7289 USING ELECTROPHYSIOLOGICAL DATA (2013 . 01) ; A61B 5 /0478 ( 2013 .01 ) ; A61B 5 /7225 ( 2013. 01 ) ; G06N 20 / 10 (2019 .01 ) (71 ) Applicant: Massachusetts Institute of Technology , Cambridge , MA (US ) ( 57 ) ABSTRACT (72 ) Inventor : Caroline Welling, Hanover, NH (US ) Embodiments related to analyzing brain activity of a subject to identify signs associated with binocular rivalry . Sensed ( 21 ) Appl. No. : 16 / 206, 639 electrical activity of a subject' s brain is received over a time period while the subject is exposed to a visual stimulus. The ( 22 ) Filed : Nov. 30 , 2018 sensed electrical activity comprises a first frequency band Related U . S . Application Data associated with a first frequency of a first image presented to the subject ' s left eye , a second frequency band associated (60 ) Provisional application No .62 / 593 , 535, filed on Dec . with a second frequency of a second image presented to the 1 , 2017 subject ' s right eye . A set of events in the time period is determined based on the frequency bands, wherein an event Publication Classification is associated with a change from a previous perceptual event (51 ) Int. Ci. to a new perceptual event. A metric for the subject is A61B 5 /0484 ( 2006 .01 ) determined based on the set of events . The metric is ana A61B 5 /00 ( 2006 .01 ) lyzed to determine whether the subject exhibits signs asso GO6N 20 / 10 (2006 .01 ) ciated with a condition that is associated with binocular A61B 5 /0478 ( 2006 .01 ) rivalry .
    [Show full text]
  • Sulphonmethane, Sulphonal, Diethylsulpho
    is a combination of amylene hydrate and chloral hydrate, superior to the corresponding compounds of other elements. while chloralose, a combination of chloral hydrate and glucose, Experience has shown that, in the main, these claims were un- partakes of the action of morphin and is rather expensive. founded, though many, even now, claim that strontium bro- Chloretone, a more recent product, is not entirely devoid of mid disturbs the stomach less than the corresponding sodium danger and is not always so certain in its action as chloral or potassium salt. Another claim that is frequently made by hydrate, while butyl chloral hydrate, or crotón chloral hydrate, manufacturers of nostrums, like "Peacock's Bromides," is that is one of the older compounds that has been found wanting and they use "chemically pure" salts. Exactly what is meant by is now little used. Of the official compounds of this group we this claim is difficult to say, but the Pharmacopeia gives us a have: number of readily applied tests by which the salts themselves Chloralamid and Paraldehyd. may be tested. The manufacturers of nostrums, on the other Chlobalformamidum.—TJ. S.—Chloralformamid. Chlorala- hand, not infrequently add the very substances that are consid- mid. This has practically the same action as therapeutic ered contaminations. doses of chloral hydrate, the latter being formed in the body by {To be continued.) decomposition of chloralformamid. Average dose: 1 gm. (15 grains). Paraldehtdum.—TJ. S.—Paraldehyd is slower in its action transparent liquid, slower in its action than chloral hydrate, but also safer. It has the disadvantage of a persistently dis- A NEW NEEDLE HOLDER.
    [Show full text]
  • Withdrawing Benzodiazepines in Primary Care
    PC\/ICU/ ADTiriC • CNS Drugs 2009,-23(1): 19-34 KtVltW MKIIWLC 1172-7047/I»/O(X)1«119/S4W5/C1 © 2009 Adis Dato Intocmation BV. All rights reserved. Withdrawing Benzodiazepines in Primary Care Malcolm Luder} Andre Tylee^ and ]ohn Donoghue^ 1 Institute of Psychiatry, King's College London, London, England 2 John Moores University, Liverpool, Scotland Contents Abstract ' 19 1. Benzodiazepine Usage 22 2. Interventions 23 2.1 Simple interventions 23 2.2 Piiarmacoiogicai interventions 25 2.3 Psychoiogical Interventions 26 2.4 Meta-Anaiysis ot Various interventions 27 3. Outcomes 28 4. Practicai Issues 29 5. Otiier Medications 30 5.1 Antidepressants 30 5.2 Symptomatic Treatments 30 6. Conciusions 31 Abstract The use of benzodiazepine anxiolytics and hypnotics continues to excite controversy. Views differ from expert to expert and from country to country as to the extent of the problem, or even whether long-term benzodiazepine use actually constitutes a problem. The adverse effects of these drugs have been extensively documented and their effectiveness is being increasingly questioned. Discontinua- tion is usually beneficial as it is followed by improved psychomotor and cognitive functioning, particularly in the elderly. The potential for dependence and addic- tion have also become more apparent. The licensing of SSRIs for anxiety disorders has widened the prescdbers' therapeutic choices (although this group of medications also have their own adverse effects). Melatonin agonists show promise in some forms of insomnia. Accordingly, it is now even more imperative that long-term benzodiazepine users be reviewed with respect to possible discon- tinuation. Strategies for discontinuation start with primary-care practitioners, who are still the main prescdbers.
    [Show full text]
  • GABA Receptors
    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: [email protected] GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis Et Al
    USOO7803838B2 (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis et al. (45) Date of Patent: Sep. 28, 2010 (54) COMPOSITIONS COMPRISING NEBIVOLOL 2002fO169134 A1 11/2002 Davis 2002/0177586 A1 11/2002 Egan et al. (75) Inventors: Eric Davis, Morgantown, WV (US); 2002/0183305 A1 12/2002 Davis et al. John O'Donnell, Morgantown, WV 2002/0183317 A1 12/2002 Wagle et al. (US); Peter Bottini, Morgantown, WV 2002/0183365 A1 12/2002 Wagle et al. (US) 2002/0192203 A1 12, 2002 Cho 2003, OOO4194 A1 1, 2003 Gall (73) Assignee: Forest Laboratories Holdings Limited 2003, OO13699 A1 1/2003 Davis et al. (BM) 2003/0027820 A1 2, 2003 Gall (*) Notice: Subject to any disclaimer, the term of this 2003.0053981 A1 3/2003 Davis et al. patent is extended or adjusted under 35 2003, OO60489 A1 3/2003 Buckingham U.S.C. 154(b) by 455 days. 2003, OO69221 A1 4/2003 Kosoglou et al. 2003/0078190 A1* 4/2003 Weinberg ...................... 514f1 (21) Appl. No.: 11/141,235 2003/0078517 A1 4/2003 Kensey 2003/01 19428 A1 6/2003 Davis et al. (22) Filed: May 31, 2005 2003/01 19757 A1 6/2003 Davis 2003/01 19796 A1 6/2003 Strony (65) Prior Publication Data 2003.01.19808 A1 6/2003 LeBeaut et al. US 2005/027281.0 A1 Dec. 8, 2005 2003.01.19809 A1 6/2003 Davis 2003,0162824 A1 8, 2003 Krul Related U.S. Application Data 2003/0175344 A1 9, 2003 Waldet al. (60) Provisional application No. 60/577,423, filed on Jun.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8.598,119 B2 Mates Et Al
    US008598119B2 (12) United States Patent (10) Patent No.: US 8.598,119 B2 Mates et al. (45) Date of Patent: Dec. 3, 2013 (54) METHODS AND COMPOSITIONS FOR AOIN 43/00 (2006.01) SLEEP DSORDERS AND OTHER AOIN 43/46 (2006.01) DSORDERS AOIN 43/62 (2006.01) AOIN 43/58 (2006.01) (75) Inventors: Sharon Mates, New York, NY (US); AOIN 43/60 (2006.01) Allen Fienberg, New York, NY (US); (52) U.S. Cl. Lawrence Wennogle, New York, NY USPC .......... 514/114: 514/171; 514/217: 514/220; (US) 514/229.5: 514/250 (58) Field of Classification Search (73) Assignee: Intra-Cellular Therapies, Inc. NY (US) None See application file for complete search history. (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 (56) References Cited U.S.C. 154(b) by 215 days. U.S. PATENT DOCUMENTS (21) Appl. No.: 12/994,560 6,552,017 B1 4/2003 Robichaud et al. 2007/0203120 A1 8, 2007 McDevitt et al. (22) PCT Filed: May 27, 2009 FOREIGN PATENT DOCUMENTS (86). PCT No.: PCT/US2O09/OO3261 S371 (c)(1), WO WOOOf77OO2 * 6, 2000 (2), (4) Date: Nov. 24, 2010 OTHER PUBLICATIONS (87) PCT Pub. No.: WO2009/145900 Rye (Sleep Disorders and Parkinson's Disease, 2000, accessed online http://www.waparkinsons.org/edu research/articles/Sleep PCT Pub. Date: Dec. 3, 2009 Disorders.html), 2 pages.* Alvir et al. Clozapine-Induced Agranulocytosis. The New England (65) Prior Publication Data Journal of Medicine, 1993, vol. 329, No. 3, pp. 162-167.* US 2011/0071080 A1 Mar.
    [Show full text]
  • SUMMARY of PRODUCT CHARACTERISTICS 1. NAME of the MEDICINAL PRODUCT XATRAL 2.5 Mg Film-Coated Tablets. XATRAL SR 5 Mg Sustained
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT XATRAL 2.5 mg film-coated tablets. XATRAL SR 5 mg sustained-release tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each Xatral 2.5 mg tablet contains 2.5mg alfuzosin hydrochloride. Each Xatral SR 5 mg tablet contains 5mg alfuzosin hydrochloride. 3. PHARMACEUTICAL FORM Xatral 2.5 mg is a white round film coated tablet for oral administration. Xatral SR 5 mg is a pale yellow biconvex film coated sustained release tablet for oral administration. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Xatral 2.5mg: Treatment of certain functional symptoms of benign prostatic hypertrophy, notably when surgery has to be delayed for whatever reason and during episodes of severe symptoms of adenoma, especially in elderly patients. Xatral SR 5 mg: Treatment of certain functional symptoms of benign prostatic hypertrophy, particularly if surgery has to be delayed for some reason. 4.2 Posology and method of administration Oral use Xatral SR 5mg tablet must be swallowed whole with a glass of water (see Section 4.4). The first dose of Xatral SR 5mg or Xatral 2.5 mg tablets should be given just before bedtime. Adults: Xatral 2.5mg: The recommended dosage is one tablet Xatral® 2.5mg three times daily. The dose may be increased to a maximum of 4 tablets (10mg) per day depending on the clinical response. ® Xatral SR 5mg: The usual dose is one Xatral SR 5 mg tablet morning and evening. Elderly patients (over 65 years) or patients treated for hypertension: Xatral 2.5mg: as a routine precaution, it is recommended that treatment be started with one Xatral 2.5 mg tablet morning and evening and that the dosage then be increased on the basis of the patient's individual response, without exceeding the maximum dosage of 4 Xatral 2.5 mg tablets daily.
    [Show full text]
  • 31V March 1891 — Insomnia As a Disease Per Se and As a Symp¬
    SYMPTOMATIC A' N D IDIOPATHIC INSOMNIA. ITS ETIOLOGY AND TREATMENT. B Y GEORGE DOUGLAS GRAY, M.B. 00O00O00O00 — 31V March 1891 — Insomnia as a disease per se and as a symp¬ tom of many diseases I have chosen as the subject of this thesis for several reasons. I have suffered . much from it myself and consequently have examined with more than ordinary clinical interest every case that has come under my notice, and in addition I have j found that, with the exception of odd notes in the medical journals, the literature on this subj.ect is comparatively rare. During this last half century since the introduction of steam power, and follov/lng it , the I "telegraph, electricity in its numerous forms, not to mention countless other time-saving devices, and with - an ever increasing population, competition or the race for life has become keener than at any " previoxis time, j -. : <■ , •- : 'V ■ " ■ ■ . - I The average human being lives at a very high pressure,! and this struggle for existence, with its concomitant 1 worries, has of late made Insomnia a much more fre¬ quent complaint than before. Indeed, in several of the older text-books on Practice of Physic (e.g. that of Dr. Hughes Bennet, published as lately as 1853) the subject is not even mentioned. In order to work well we must eat well and sleep well: loss of appet¬ ite and lowering of all bodily functions soon follow loss of sleep,therefore all the more important is it that the etiology and treatment of Insomnia should be thoroughly understood.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Pharmacological Properties of GABAA- Receptors Containing Gamma1
    Molecular Pharmacology Fast Forward. Published on November 4, 2005 as DOI: 10.1124/mol.105.017236 Molecular PharmacologyThis article hasFast not Forward.been copyedited Published and formatted. on The November final version 7, may 2005 differ as from doi:10.1124/mol.105.017236 this version. MOLPHARM/2005/017236 Pharmacological properties of GABAA- receptors containing gamma1- subunits Khom S.1, Baburin I.1, Timin EN, Hohaus A., Sieghart W., Hering S. Downloaded from Department of Pharmacology and Toxicology, University of Vienna Center of Brain Research , Medical University of Vienna, Division of Biochemistry and molpharm.aspetjournals.org Molecular Biology at ASPET Journals on September 27, 2021 1 Copyright 2005 by the American Society for Pharmacology and Experimental Therapeutics. Molecular Pharmacology Fast Forward. Published on November 4, 2005 as DOI: 10.1124/mol.105.017236 This article has not been copyedited and formatted. The final version may differ from this version. MOLPHARM/2005/017236 Running Title: GABAA- receptors containing gamma1- subunits Corresponding author: Steffen Hering Department of Pharmacology and Toxicology University of Vienna Althanstrasse 14 Downloaded from A-1090 Vienna Telephone number: +43-1-4277-55301 Fax number: +43-1-4277-9553 molpharm.aspetjournals.org [email protected] Text pages: 29 at ASPET Journals on September 27, 2021 Tables: 2 Figures: 7 References: 26 Abstract: 236 words Introduction:575 words Discussion:1383 words 2 Molecular Pharmacology Fast Forward. Published on November 4, 2005 as DOI: 10.1124/mol.105.017236 This article has not been copyedited and formatted. The final version may differ from this version. MOLPHARM/2005/017236 Abstract GABAA receptors composed of α1, β2, γ1-subunits are expressed in only a few areas of the brain and thus represent interesting drug targets.
    [Show full text]
  • 5-HT Receptor Agonist Befiradol Reduces Fentanyl-Induced
    5-HT1A Receptor Agonist Befiradol Reduces Fentanyl-induced Respiratory Depression, Analgesia, and Sedation in Rats Jun Ren, Ph.D., Xiuqing Ding, B.Sc., John J. Greer, Ph.D. ABSTRACT Background: There is an unmet clinical need to develop a pharmacological therapy to counter opioid-induced respiratory depression without interfering with analgesia or behavior. Several studies have demonstrated that 5-HT1A receptor agonists alleviate opioid-induced respiratory depression in rodent models. However, there are conflicting reports regarding their effects on analgesia due in part to varied agonist receptor selectivity and presence of anesthesia. Therefore the authors performed a Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/122/2/424/267207/20150200_0-00031.pdf by guest on 27 September 2021 study in rats with befiradol (F13640 and NLX-112), a highly selective 5-HT1A receptor agonist without anesthesia. Methods: Respiratory neural discharge was measured using in vitro preparations. Plethysmographic recording, nociception testing, and righting reflex were used to examine respiratory ventilation, analgesia, and sedation, respectively. Results: Befiradol (0.2 mg/kg, n = 6) reduced fentanyl-induced respiratory depression (53.7 ± 5.7% of control minute ven- tilation 4 min after befiradol vs. saline 18.7 ± 2.2% of control, n = 9; P < 0.001), duration of analgesia (90.4 ± 11.6 min vs. saline 130.5 ± 7.8 min; P = 0.011), duration of sedation (39.8 ± 4 min vs. saline 58 ± 4.4 min; P = 0.013); and induced baseline hyperventilation, hyperalgesia, and “behavioral syndrome” in nonsedated rats. Further, the befiradol-induced alleviation of opioid-induced respiratory depression involves sites or mechanisms not functioning in vitro brainstem–spinal cord and medul- lary slice preparations.
    [Show full text]